Sitagliptin Tablets 100 mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
MFDS item code 201502209 · Approved 2015.04.14
This product's status changed to Expired on 2025.04.14. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help control blood sugar in patients with type 2 diabetes. It can be administered alone and may be combined with metformin in cases where blood sugar control is difficult with monotherapy, especially in patients without prior experience of diabetes treatment. Furthermore, it can be added to therapy when adequate blood sugar control is not achieved with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin. Additionally, it can improve effectiveness even when various medications are combined but blood sugar control remains inadequate. This drug aids in the improvement of blood sugar control through these diverse methods of administration.
This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is necessary, evaluation of renal function before and periodically after starting this medicine is recommended. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication is used for the treatment of diabetes, and serious allergic reactions may occur in some patients. Such reactions can manifest within the first three months after taking the medication, with symptoms such as rash or swelling appearing on the skin, so caution is advised. Additionally, pancreatitis may develop during treatment, demonstrated by abdominal pain, vomiting, and nausea; patients should consult a physician immediately if these symptoms occur. This drug should not be used in patients with type 1 diabetes or those with specific allergies, and dosage adjustments may be required for patients with impaired renal function. Common side effects reported in clinical trials include upper respiratory infections, headache, nasopharyngitis, diarrhea, nausea, etc., and hypoglycemic symptoms may occur, making tight blood sugar control critical. Caution is especially necessary when used with insulin or sulfonylureas as the risk of hypoglycemia may increase. This drug is not recommended for pregnant women, and breastfeeding women should also avoid its use. Safety in children and adolescents under 18 years of age has not been established. In case of overdose, general emergency care should be given, and if necessary, the drug may be removed through hemodialysis. If symptoms such as joint pain or skin blistering occur during the use of this drug, it is imperative to consult a healthcare professional immediately, and the medication should be discontinued if such symptoms arise. Lastly, this drug has the potential for interactions with other medications; therefore, it is essential to inform the physician or pharmacist about any other medications being taken, particularly when taking it alongside cyclosporine or digoxin.
anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is also recommended to store it at room temperature between 1°C to 30°C.
Beige colored, round, biconvex film-coated tablet
Company packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.